Programme SOM0044 for Parkinson’s Disease
SOM0044 is a small molecule for the treatment of Parkinson’s disease.
SOM0044 is a small molecule for the treatment of Parkinson’s disease.
Parkinson’s disease is a slowly progressive neurodegenerative disorder characterised by bradykinesia, rigidity, tremor at rest, shuffling gait and postural instability. The disease is caused by ageing, genetic and environmental factors. Symptoms usually appear around 60 years of age. Affects an estimated 10 million people worldwide. Available treatments are symptomatic, mainly involving dopaminergic agents for the control of motor function.
Unique advantages of SOMAI PRO include identification of new mechanisms of action of drugs (biological activity defined by Molecular Field Maps, which were not described...
The current Covid-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility.
Product enquiry
Thank you for submitting the form. Your enquiry will be submitted to the company.